Clinical Trial

Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)

Study acronym: PrEcISE
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 29, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This double-blind, 12-week study will consist include132 anxious youth who are randomized (1:1) to standard or pharmacogenetically-guided escitalopram dosing. Block randomization (1:1) will be stratified by sex and metabolizer status.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-11-04; most recent amendment 2024-08-28.
Status change: Not Yet Recruiting → Recruiting 2021-05-03
Trial Details
NCT Number NCT04623099
Lead Sponsor University of Cincinnati
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions Anxiety
Enrollment 132 participants
Start Date 2021-03-08
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-29